Gene hunt aims to unlock NF1's mysteries
NCT ID NCT00111384
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 6 times
Summary
This study looks at people with neurofibromatosis type 1 (NF1) and their families to find out why some have more severe symptoms than others. Researchers will collect medical history, blood samples, and images to study genes and physical traits. The goal is to identify genes that influence disease severity and better understand rare features of NF1.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify genes that predict the severity of NF1, leading to better monitoring and personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly improve health outcomes, and results may take years to apply in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEGIUS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World study tracks Selumetinib's impact on NF1 tumors in children
- Could a cholesterol drug boost reading skills in kids with NF1?
- Antioxidant drug shows promise for kids with NF1
- Can a simple walk test spot motor trouble in kids with NF1?
- New drug aims to help kids with rare genetic short stature grow taller
- New study tracks Long-Term safety of NF1 drug in kids